AIM ImmunoTech

$2.26
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.09 (-3.83%) Today
$0.00 (0.00%) As of 12:59 AM UTC after-hours

Why Robinhood?

You can buy or sell AIM ImmunoTech and other stocks, options, and ETFs commission-free!

About AIM

AIM ImmunoTech, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Orlando, FL. The listed name for AIM is AIM ImmunoTech Inc.

CEO
Thomas Kenwood Equels
Employees
26
Headquarters
Ocala, Florida
Founded
1966
Market Cap
88.43M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
2.35M
High Today
$2.37
Low Today
$2.21
Open Price
$2.30
Volume
1.17M
52 Week High
$7.11
52 Week Low
$1.35

AIM Earnings

-$1.13
-$0.75
-$0.38
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 30, After Hours

You May Also Like

ITT
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure